文献速递免疫规划卫生政策与健康促进

澳大利亚青少年MenACWY结合疫苗成本效果分析

Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
PubMed 文献 · Vaccine · 2019-07-10

研究用马尔可夫模型模拟澳大利亚0-84岁人群侵袭性脑膜炎球菌病(IMD)的发病与后果,随访至85岁,从卫生系统角度比较15-19岁接种MenACWY结合疫苗与不接种的成本效果。结果显示该程序可预防1664例IMD,获得1131生命年和2058质量调整生命年(QALY),增量成本效果比为每QALY 55,857澳元;在每QALY 50,000澳元支付意愿阈值下具有成本效果的概率为34.6%。

要点

  • 15-19岁接种MenACWY可预防1664例IMD,获得2058 QALY。
  • 增量成本效果比为每生命年101,649澳元、每QALY 55,857澳元。
  • 每QALY 50,000澳元阈值下具有成本效果的概率为34.6%。

核心结论

  • 在每QALY 50,000澳元支付意愿阈值下,该青少年MenACWY接种程序具有成本效果的可能性为35%。

研究设计与样本

  • 构建马尔可夫模型模拟澳大利亚0-84岁人群IMD发病与后果,随访至85岁。
  • 模型含四个健康状态:无既往IMD存活、IMD后无长期并发症存活、IMD后有长期并发症存活、死亡。
  • 从澳大利亚卫生系统角度进行决策分析,比较接种程序与不接种,成本和健康结局按每年5%贴现(基础分析)。
  • IMD年龄别发病率和病死率来自澳大利亚监测数据,疫苗覆盖率、效力和群体免疫基于已发表数据。

主要发现

  • 与不接种相比,针对15-19岁澳大利亚人的MenACWY接种程序预期在0-84岁人群随访至85岁期间预防1664例IMD。
  • 增量成本效果比为每生命年101,649澳元和每QALY 55,857澳元。
  • 概率敏感性分析显示,在每QALY 50,000澳元支付意愿阈值下具有成本效果的可能性为34.6%。

关键数值与推荐

  • MenACWY接种总成本为每剂56澳元。
  • 成本与健康结局贴现率为每年5%(基础分析)。
  • 支付意愿阈值为每QALY 50,000澳元。
  • 增量成本效果比:每生命年101,649澳元,每QALY 55,857澳元。

临床怎么用

  • 为澳大利亚15-19岁青少年接种MenACWY的成本效果评估提供模型证据,可辅助免疫规划决策。
  • 在每QALY 50,000澳元阈值下成本效果概率约35%,需结合支付意愿与预算影响判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The incidence of invasive meningitis disease (IMD) is increasing in Australia. A conjugate vaccine of meningococcal polysaccharide serogroups A, C, W and Y (MenACWY) is currently indicated for infants aged 12 months on the Australian National Immunisation Program. This study sought to determine the cost-effectiveness of a broader MenACWY vaccination program for Australians aged 15 to 19 years. METHODS: A Markov model was constructed to simulate the incidence and consequences of IMD in Australians aged 0-84 years, with follow up until age 85 years. The model comprised four health states: 'Alive with no previous IMD', 'Alive, post IMD without long-term complications', 'Alive, post IMD with long-term complications' and 'Dead'. Decision analysis compared the clinical consequences and costs of a vaccination program versus no vaccination from the perspective of the Australian health care system. Age-specific incidence of IMD and fatality rates were derived from Australian surveillance data. Vaccine coverage, vaccine efficacy and herd immunity were based on published data. The total cost for MenACWY vaccination was AU$56 per dose. Costs and health outcomes were discounted by 5% per annum (in the base-case analysis). RESULTS: Compared to no vaccination, a MenACWY vaccination program targeted at Australians aged 15-19 years was expected to prevent 1664 IMD cases in the Australian population aged 0-84 years followed up until age 85 years. The program would lead to 1131 life years (LYs) and 2058 quality adjusted life years (QALYs) gained at a total cost of AU$115 million (all discounted values). These equated to incremental cost-effectiveness ratios of AU$101,649 per LY gained and AU$55,857 per QALY gained. A probabilistic sensitivity analysis demonstrated a likelihood of cost-effectiveness of 34.6%, assuming a willingness to pay threshold of AU$50,000 per QALY gained. CONCLUSION: The likelihood of this program being cost-effective under a willingness to pay threshold AU$50,000 per QALY gained is 35%.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Si S, Zomer E, Fletcher S, et al. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents. Vaccine. 2019. PMID: 31301916. doi:10.1016/j.vaccine.2019.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。